Senti Biosciences is a synthetic biology company headquartered in South San Francisco, California, and was founded in 2016 by Jim Collins, Philip Lee, Tim Lu, and Wilson Wong. Senti Biosciences has a proprietary synthetic biology platform for the development of therapeutics. The company uses genetic circuits to program cell therapies so that they have localized action, sensors, dynamic responses, and safety control.
Gary Lee, Ph.D.
Chief Scientific Officer
Philip Lee, Ph.D.
Curt Herberts, M.B.S.
Chief Financial Officer and Chief Business Officer
Jim Collins, Ph.D.
Tim Lu, M.D., Ph.D.
Wilson Wong, Ph.D.
Documentaries, videos and podcasts
- ImmunotherapyImmunotherapy aims to treat disease through activation or suppression of an immune response. For example activating immunotherapies can target cancer and suppressive immunotherapies can target autoimmunity.
- Chimeric antigen receptorA lab engineered receptor designed to bind certain proteins, such as surface proteins on cancer cells, that is added to immune cells for immunotherapy strategies such as directing T cells to fight cancer.
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Synthetic biologyInterdisciplinary branch of biology and engineering, applying multiple disciplines to build artificial biological systems for research, engineering, and medical applications.